Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Meng‐Jia Song"'
Autor:
Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang, Ming-Yuan Chen, Gang Ma, Ling Guo, Jian-Chuan Xia
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/ba71c9b1b1fe4145b05022e7b1aa3434
Autor:
Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang, Ming-Yuan Chen, Gang Ma, Ling Guo, Jian-Chuan Xia
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-16 (2020)
Abstract Background Clinically, the median survival in patients with metastatic renal cell carcinoma (RCC) was only 6–12 months and a 5-year survival rate of less than 20%. Therefore, an in-depth study of the molecular mechanisms involved in RCC is
Externí odkaz:
https://doaj.org/article/adf556a0a1964c06ad93d70cfbcfc683
Autor:
Meng‐Jia Song, Qiu‐Zhong Pan, Ya Ding, Jianxiong Zeng, Pei Dong, Jing‐Jing Zhao, Yan Tang, Jingjing Li, Zhiling Zhang, Junyi He, Jieying Yang, Yue Huang, Ruiqing Peng, Qi‐Jing Wang, Jia‐Mei Gu, Jia He, Yong‐Qiang Li, Shi‐Ping Chen, Rongxing Huang, Zi‐Qi Zhou, Chaopin Yang, Yulong Han, Hao Chen, Heping Liu, Shangzhou Xia, Yang Wan, De‐Sheng Weng, Liming Xia, Fang‐Jian Zhou, Jian‐Chuan Xia
Publikováno v:
Clinical & Translational Immunology, Vol 10, Iss 3, Pp n/a-n/a (2021)
Abstract Objectives Although axitinib has achieved a preferable response rate for advanced renal cell carcinoma (RCC), patient survival remains unsatisfactory. In this study, we evaluated the efficacy and safety of a combination treatment of axitinib
Externí odkaz:
https://doaj.org/article/207802f67c564291ab3647874de5462f
Autor:
Qiu-Zhong Pan, Jing-Jing Zhao, Chao-Pin Yang, Yu-Qing Zhou, Jun-Zhong Lin, Yan Tang, Jia-Mei Gu, Qi-Jing Wang, Yong-Qiang Li, Jia He, Shi-Ping Chen, Meng-Jia Song, Yue Huang, Jie-Ying Yang, De-Sheng Weng, Jian-Chuan Xia
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Adjuvant chemotherapy after surgery is the standard treatment modality for stage III and part of stage II or stage IV colorectal cancer (CRC) patients. However, the 5-year overall survival (OS) rate remains unsatisfactory. Thus, developing combinatio
Externí odkaz:
https://doaj.org/article/808971fc44914db7b98dbeeccb0665b0
Autor:
Qiu‐Zhong Pan, Jia‐Mei Gu, Jing‐Jing Zhao, Yan Tang, Qi‐Jing Wang, Qian Zhu, Meng‐Jia Song, Yong‐Qiang Li, Jia He, Shi‐Ping Chen, De‐Sheng Weng, Jian‐Chuan Xia
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 2, Pp n/a-n/a (2020)
Abstract Objectives Fluoropyrimidine‐based chemotherapy regimens are the current first‐line treatment for metastatic colorectal cancer (mCRC); however, the outcome is often unsatisfactory. The present study aimed to determine the effect of combin
Externí odkaz:
https://doaj.org/article/8033bc0eb1bd4584867b6ce545809720
Autor:
Meng, Jia-Song1,2 (AUTHOR), Tang, Yu-Han2,3 (AUTHOR), Sun, Jing1,2 (AUTHOR), Zhao, Da-Qiu1,2 (AUTHOR), Zhang, Ke-Liang1,2 (AUTHOR), Tao, Jun1,2 (AUTHOR) taojun@yzu.edu.cn
Publikováno v:
BMC Genomics. 2/1/2021, Vol. 22 Issue 1, p1-21. 21p.
Autor:
Jia He, Jun-Zhong Lin, J. Yang, Qiu-Zhong Pan, Yan Tang, Shi-Ping Chen, Qijing Wang, Jian-Chuan Xia, Yongqiang Li, Meng-Jia Song, Chaopin Yang, Jia-Mei Gu, De-Sheng Weng, Jing Jing Zhao, Yue Huang, Yu Qing Zhou
Publikováno v:
Oncoimmunology
OncoImmunology, Vol 9, Iss 1 (2020)
OncoImmunology, Vol 9, Iss 1 (2020)
Adjuvant chemotherapy after surgery is the standard treatment modality for stage III and part of stage II or stage IV colorectal cancer (CRC) patients. However, the 5-year overall survival (OS) rate remains unsatisfactory. Thus, developing combinatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1e00537c997f7e6c383498f3d8bf887
https://doi.org/10.1080/2162402x.2020.1752563
https://doi.org/10.1080/2162402x.2020.1752563
Autor:
Wan Ming Hu, Ling Guo, Yan Tang, Jing Jing Zhao, Ai Lin Zhong, Meng Jia Song, Jian Chuan Xia, Qiu Zhong Pan, Gang Ma, Ming Yuan Chen, Chao Pin Yang, Tong Xiang, Yuan Liu, De Sheng Weng, Min Li, Qian Zhu, Hao Hu, Jie Ying Yang, Jun Yi He, Zi Qi Zhou
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-16 (2020)
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-16 (2020)
Background Clinically, the median survival in patients with metastatic renal cell carcinoma (RCC) was only 6–12 months and a 5-year survival rate of less than 20%. Therefore, an in-depth study of the molecular mechanisms involved in RCC is of great
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50d0252600f3a71a8d83ab1ffeb90977
http://europepmc.org/articles/PMC6942383
http://europepmc.org/articles/PMC6942383
Autor:
Zhu, Qian, Zhong, Ai-Lin, Hu, Hao, Zhao, Jing-Jing, Weng, De-Sheng, Tang, Yan, Qiu-Zhong Pan, Zhou, Zi-Qi, Meng-Jia Song, Yang, Jie-Ying, He, Jun-Yi, Liu, Yuan, Li, Min, Hu, Wan-Ming, Chao-Pin Yang, Xiang, Tong, Chen, Ming-Yuan, Ma, Gang, Guo, Ling, Jian-Chuan Xia
Additional file 1: Table S1. The sequences of the primers used for amplifying AGK and GAPDH. Table S2. The primary antibodies of Western blotting. Table S3. Association between the absolute IHC score of AGK expression and the clinicopathological feat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36670d9286de353d7a8db831f05a4090
